Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy
Authors:
Open Access
Abstract
BACKGROUND: The evaluation of residual disease (RD) after chemoradiation therapy (CRT) in stage IB2/II cervical carcinoma conventionally is based on a clinical examination and magnetic resonance imaging (MRI) performed 3 to 8 weeks after the end of treatment. Very few studies have correlated MRI and histologic findings specifically in cervix cancer. This was the objective of the current study.METHODS: A retrospective review was undertaken of patients who fulfilled the following inclusion criteria: 1) stage IB2/II cervical cancer, 2) external radiotherapy (45 grays [Gy]) was given with concomitant chemotherapy followed by uterovaginal brachytherapy (15 Gy), 3) MRI studies were obtained between 3 weeks and 8 weeks after brachytherapy, and 4) completion surgery included at least a hysterectomy. Postsurgical histologic findings and MRI results were compared.RESULTS: Forty‐four patients who were treated between 2003 and 2006 fulfilled all inclusion criteria. Twelve patients (27%) had achieved a radiologic complete response, 16 patients (36.5%) had unclassified lesions (RD or ‘fibrosis’), and 16 patients (36.5%) had radiologic residual tumor. According to the histologic results, 19 patients (43%) had no RD, 10 patients (23%) had inframillimeter RD, 2 patients (5%) had RD that measured 1 cm. The sensitivity and specificity of MRI in evaluating RD were 80% and 55%, respectively.CONCLUSIONS: The current results indicated that the evaluation of RD 3 to 8 weeks after CRT with MRI is difficult, and the risk of false‐positive results is high. Another radiologic procedure or a more technologically advanced MRI technique, such as diffusion‐weighted MRI, should be evaluated. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI☆Gynecologic Oncology, 2007
- The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancerGynecologic Oncology, 2007
- Para-Aortic Involvement and Interest of Para-Aortic Lymphadenectomy after Chemoradiation Therapy in Patients with Stage IB2 and II Cervical Carcinoma Radiologically Confined to the Pelvic CavityAnnals of Surgical Oncology, 2007
- The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapyInternational Journal of Gynecological Cancer, 2007
- Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinomaEuropean Journal of Surgical Oncology, 2007
- Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: Morbidity and outcome: Results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer)Gynecologic Oncology, 2006
- Preoperative chemoradiotherapy in locally advanced cervical cancer: Long-term outcome and complicationsGynecologic Oncology, 2005
- Results of Hysterectomy in Patients With Bulky Residual Disease at the End of Chemoradiotherapy for Stage IB2/II Cervical CarcinomaAnnals of Surgical Oncology, 2005
- Cervical carcinoma: Computed tomography and magnetic resonance imaging for preoperative stagingObstetrics & Gynecology, 1995
- Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervixGynecologic Oncology, 1990